Skip to main content
. 2018 Apr 25;3(Suppl 1):e000359. doi: 10.1136/esmoopen-2018-000359

Figure 2.

Figure 2

Evaluation of risk of bleeding according to tumour growth. TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.